[Skip to Content]
[Skip to Content Landing]
Views 212
Citations 0
Comment & Response
March 2016

340B Drug Pricing Program Reform

Author Affiliations
  • 1Medical Oncology Association of Southern California, Upland, California
JAMA Oncol. 2016;2(3):403. doi:10.1001/jamaoncol.2015.5400

To the Editor A recent Viewpoint1 in JAMA Oncology defends maintaining the 340B Drug Pricing Program under its current form despite widespread fraud and abuse. Established by Congress in 1992, the 340B Drug Pricing Program requires pharmaceutical manufacturers to supply sharply discounted drugs to health care facilities that serve high volumes of poor, indigent, uninsured, or otherwise vulnerable patients.2